feed,title,long_url,short_url
Benzinga,Continued survival benefit in Targovax's ONCOS-102 trial in mesothelioma at the 21-month follow-up,https://benzinga.com/pressreleases/21/02/n19789255/continued-survival-benefit-in-targovaxs-oncos-102-trial-in-mesothelioma-at-the-21-month-follow-up,
